Surgical and oncological outcomes of sentinel lymph node sampling in elderly patients with intermediate to high-risk endometrial carcinoma.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
04 07 2022
Historique:
pubmed: 10 6 2022
medline: 28 9 2022
entrez: 9 6 2022
Statut: epublish

Résumé

We aimed to evaluate the surgical and oncological outcomes of elderly patients with intermediate to high-risk endometrial cancer undergoing staging with sentinel lymph node (SLN) sampling and pelvic lymphadenectomy. We conducted a retrospective study of elderly (>65-year-old) patients diagnosed with endometrial cancer between December 2007 and August 2017. These patients had been treated at a single center in Montreal, Canada. We compared the surgical and oncological outcomes of three cohorts undergoing surgical staging in non-overlapping eras: 1) lymphadenectomy, 2) lymphadenectomy and SLN sampling, 3) SLN sampling alone. Using life tables, Kaplan-Meier survival curves and log-rank tests, we analyzed 2-year progression-free survival, overall survival, and disease-specific survival. Our study included 278 patients with a median age of 73 years (range; 65-91): 84 (30.2%) underwent lymphadenectomy, 120 (43.2%) underwent SLN sampling with lymphadenectomy, and 74 (26.6%) had SLN sampling alone. The SLN sampling alone group had shorter operative times with a median duration of 199 minutes (range, 75-393) compared with 231 (range, 125-403) and 229 (range, 151-440) minutes in the SLN sampling with lymphadenectomy and lymphadenectomy cohorts; respectively (p<0.001). The SLN sampling alone group also had lower estimated blood loss with a median loss of 20 mL (range, 5-150) vs 25 mL (range, 5-800) and 40 mL (range, 5-400) in the SLN sampling with lymphadenectomy and lymphadenectomy cohorts, respectively (p=0.002). The 2 year overall survival and progression-free survival were not significantly different between the three groups (p=0.45, p=0.51, respectively). On multivariable analysis after adjusting for age, American Society of Anesthesiologists (ASA) score, stage, grade, and lymphovascular space invasion, adding SLN sampling was associated with better overall survival, (HR 0.2, CI [0.1 to 0.6], p=0.006) and progression-free survival (HR 0.5, CI [0.1 to 1.0], p=0.05). Sentinel lymph node-based surgical staging is feasible and associated with better surgical outcomes and comparable oncological outcomes in elderly patients with intermediate and high

Identifiants

pubmed: 35680137
pii: ijgc-2022-003431
doi: 10.1136/ijgc-2022-003431
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

875-881

Informations de copyright

© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Emad Matanes (E)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada emad.matanes@gmail.com.
Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Neta Eisenberg (N)

Yitzhak Shamir Medical Center Assaf Harofeh, Zerifin, Center, Israel.

Cristina Mitric (C)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Amber Yasmeen (A)

Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Sara Ismail (S)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Oded Raban (O)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Tal Cantor (T)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

David Knigin (D)

Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Susie Lau (S)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Shannon Salvador (S)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Walter Gotlieb (W)

Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

Liron Kogan (L)

Department of Obstetrics and Gynecology, Hadassah Medical Center, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH